Brimapitide

Drug Profile

Brimapitide

Alternative Names: AM-111; AM111 peptide; D-JNKI-1; XG-102; XG102 peptide

Latest Information Update: 30 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Xigen
  • Developer Auris Medical; ribOvax Biotechnologies; Xigen
  • Class Cardiovascular therapies; Eye disorder therapies; Neuroprotectants; Peptides; Urologics
  • Mechanism of Action Mitogen-activated protein kinase 8 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sensorineural hearing loss
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Ocular inflammation; Sensorineural hearing loss
  • Preclinical Alzheimer's disease; Interstitial cystitis; Kidney disorders
  • No development reported Eye disorders; Stroke
  • Discontinued Ear disorders; Myocardial infarction; Parkinson's disease; Transplant rejection

Most Recent Events

  • 29 Nov 2017 Efficacy data from the phase III HEALOS trial for Sensorineural hearing loss released by Auris Medical
  • 29 Nov 2017 Auris Medical terminates the phase III ASSENT trial in Sensorineural hearing in USA, Canada and South Korea
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Ocular-inflammation(In volunteers) in Switzerland (Subconjunctival, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top